Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund (BIVF) is the corporate venture arm of pharma group Boehringer Ingelheim, launched in 2010 and headquartered in Ingelheim am Rhein, Germany. It runs a 350 million euro evergreen fund investing globally (EU, US, China) as a dedicated Seed/Series A biotech investor, backing first-in-class disease-modifying therapeutics across immuno-oncology, regenerative medicine, auto-immunity, anti-infectives (AMR) and digital health. It typically takes a minority stake with a board seat, has invested in over 70 companies, and has produced multiple exits including six acquisitions by its own parent.
AUM
€350M
Funds
1
vintages 2010
Portfolio
30
Exits
12
SectorsHealthcare
Key facts
Recent exits
AgomAb Therapeutics
Biotech · 2026 · 7yr hold
ImCheck Therapeutics
Biotech · 2025 · 8yr hold
T3 Pharmaceuticals
Biotech · 2023 · 4yr hold
ArmaGen Technologies
Biotech · 2020 · 6yr hold
Coverage notes
1 fund tracked, 42 portfolio companies (30 active · 12 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Boehringer Ingelheim Venture Fund has raised, with its portfolio companies. Hand-checked from public filings.
1 fund
Boehringer Ingelheim Venture FundEvergreen2010 · 16yr€350M30 active · 12 realized
Unrealized
30 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Abalos Therapeutics | Biotech | Germany | 2019 |
| Acousia Therapeutics | Biotech | Germany | 2012 |
| Aignostics | Healthcare | Germany | 2020 |
| ArrePath | Biotech | United States | 2021 |
| Asgard Therapeutics | Biotech | Sweden | 2021 |
| Aurobac Therapeutics | Biotech | France | 2023 |
| Bodyport | HealthTech | United States | 2020 |
| Brainomix | Healthcare | United Kingdom | 2018 |
| C-mo Medical Solutions | HealthTech | Portugal | 2022 |
| Centauri Therapeutics | Biotech | United Kingdom | 2022 |
| DiogenX | Biotech | France | 2020 |
| Glox Therapeutics | Biotech | United Kingdom | 2023 |
| HepaRegenix | Biotech | Germany | 2016 |
| Libra Therapeutics | Biotech | United States | 2020 |
| Nuevocor | Biotech | Singapore | 2021 |
| Obulytix | Biotech | Belgium | 2023 |
| ProTgen | Biotech | United States | 2024 |
| QUANTRO Therapeutics | Biotech | Austria | 2020 |
| Refoxy Pharmaceuticals | Biotech | Germany | 2024 |
| Rewind Therapeutics | Biotech | Belgium | 2017 |
| Rgenta | Biotech | United States | 2019 |
| RiboX Therapeutics | Biotech | China | 2021 |
| RinRi Therapeutics | Biotech | United Kingdom | 2019 |
| smartbax | Biotech | Germany | 2021 |
| STRM.BIO | Biotech | United States | 2021 |
| SwitchKine | Biotech | Switzerland | 2024 |
| Synthetica Pioneering | Biotech | China | 2024 |
| Tacalyx | Biotech | Germany | 2019 |
| TECregen | Biotech | Switzerland | 2023 |
| Topas Therapeutics | Biotech | Germany | 2017 |
Abalos TherapeuticsActive
BiotechGermany· Entry 2019
Acousia TherapeuticsActive
BiotechGermany· Entry 2012
AignosticsActive
HealthcareGermany· Entry 2020
ArrePathActive
BiotechUnited States· Entry 2021
Asgard TherapeuticsActive
BiotechSweden· Entry 2021
Aurobac TherapeuticsActive
BiotechFrance· Entry 2023
BodyportActive
HealthTechUnited States· Entry 2020
BrainomixActive
HealthcareUnited Kingdom· Entry 2018
C-mo Medical SolutionsActive
HealthTechPortugal· Entry 2022
Centauri TherapeuticsActive
BiotechUnited Kingdom· Entry 2022
DiogenXActive
BiotechFrance· Entry 2020
Glox TherapeuticsActive
BiotechUnited Kingdom· Entry 2023
HepaRegenixActive
BiotechGermany· Entry 2016
Libra TherapeuticsActive
BiotechUnited States· Entry 2020
NuevocorActive
BiotechSingapore· Entry 2021
ObulytixActive
BiotechBelgium· Entry 2023
ProTgenActive
BiotechUnited States· Entry 2024
QUANTRO TherapeuticsActive
BiotechAustria· Entry 2020
Refoxy PharmaceuticalsActive
BiotechGermany· Entry 2024
Rewind TherapeuticsActive
BiotechBelgium· Entry 2017
RgentaActive
BiotechUnited States· Entry 2019
RiboX TherapeuticsActive
BiotechChina· Entry 2021
RinRi TherapeuticsActive
BiotechUnited Kingdom· Entry 2019
smartbaxActive
BiotechGermany· Entry 2021
STRM.BIOActive
BiotechUnited States· Entry 2021
SwitchKineActive
BiotechSwitzerland· Entry 2024
Synthetica PioneeringActive
BiotechChina· Entry 2024
TacalyxActive
BiotechGermany· Entry 2019
TECregenActive
BiotechSwitzerland· Entry 2023
Topas TherapeuticsActive
BiotechGermany· Entry 2017
Realized
12 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| AgomAb Therapeutics | Biotech | Belgium | 2019 | 2026 | IPO | – | – |
| Amal Therapeutics | Biotech | Switzerland | 2016 | 2019 | Trade Sale | – | |
| ArmaGen Technologies | Biotech | United States | 2014 | 2020 | Trade Sale | – | |
| Hookipa Pharma | Biotech | Austria | 2013 | 2019 | – | – | – |
| ImCheck Therapeutics | Biotech | France | 2017 | 2025 | Trade Sale | – | |
| NBE Therapeutics | Biotech | Switzerland | 2013 | 2020 | Trade Sale | – | |
| Okairos | Biotech | Switzerland | 2011 | 2013 | Trade Sale | – | |
| Rigontec | Biotech | Germany | 2014 | 2017 | Trade Sale | – | |
| STAT-Dx | HealthTech | Spain | 2013 | 2018 | Trade Sale | – | |
| T3 Pharmaceuticals | Biotech | Switzerland | 2019 | 2023 | Trade Sale | – | |
| Tilos Therapeutics | Biotech | United States | 2016 | 2019 | Trade Sale | – | |
| ViraTherapeutics | Biotech | Austria | 2013 | 2018 | Trade Sale | – |
Hookipa PharmaExited 2019
BiotechAustria· Entry 2013
Track Boehringer Ingelheim Venture Fund
Saved GPs appear in your watchlist, one click from your workspace.
Similar firms
Other private equity firms tracked on GP Intel.
Athos
Germany·€20.0BTarget Global
Germany·€3.0BHV Capital
Germany·€2.8BBertelsmann Investments
Germany·€2.3BRocket Internet SE
Germany·€1.9BGlobal Founders Capital
Germany·€1.8BLeaps by Bayer
Germany·€1.8BAllianz X
Germany·€1.5BPicus Capital
Germany·€1.5BCherry Ventures
Germany·€1.4Bdievini Hopp BioTech holding
Germany·€1.4BMIG Capital
Germany·€1.3BLast updated July 2026 · Sourced from public filings